Here’s a podcast of my recent Guardian column, Why all pharmaceutical research should be made open access:
One of the strongest arguments for public access in scholarly and scientific publication is the “public debt” argument: if the public pays you to do research, the research should belong to the public. That’s a good argument, but it’s not the whole story. For one thing, it’s vulnerable to the “public-private partnership” counterargument, which goes, “Ah, yes, but why not ensure that the public gets a maximum dividend on its spending by charging lots of money for access to publicly funded research and returning the profit to the research sector?” I think this argument is rubbish, as do most economists who have studied the question.
The public good of freely accessible, unencumbered research generates more economic value for the public than the quick-hit sugar-rush you get from charging the public on the way in and again on the way out. This has held true in many sectors, though the canonical example is the massive public return from the US Geological Survey’s freely usable maps, which have generated a fortune that makes the ransoms collected by the Ordinance Survey on its maps of the UK look like a pittance.
Mastering by John Taylor Williams: firstname.lastname@example.org
John Taylor Williams is a audiovisual and multimedia producer based in Washington, DC and the co-host of the Living Proof Brew Cast. Hear him wax poetic over a pint or two of beer by visiting livingproofbrewcast.com. In his free time he makes “Beer Jewelry” and “Odd Musical Furniture.” He often “meditates while reading cookbooks.”